H-100, a topically applied gel composed of nicardipine, superoxide dismutase and emu oil, shows promise for the treatment of Peyronie's disease, say researchers. In the study, 11 patients received H-100 for 3 months and 11 patients received placebo for 3 months. All 22 patients then received H-100 for an additional 3 months. H-100 treatment was associated with increased mean stretched penile length, reduced mean penile curvature and reduced mean pain level. Placebo was only associated with a small improvement in mean stretched penile length. Improvements in all parameters were seen in patients who switched from placebo to H-100 treatment.
References
Twidwell, J. & Levine, L. Topical treatment for acute phase Peyronie's disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study. Int. J. Impot. Res. http://dx.doi.org/10.1038/ijir.2015.22 (2015)
Rights and permissions
About this article
Cite this article
Kelsey, R. Novel topical gel treatment for Peyronie's disease. Nat Rev Urol 13, 64 (2016). https://doi.org/10.1038/nrurol.2016.6
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.6